Search results
Results from the WOW.Com Content Network
Meningococcal vaccines are generally safe. [9] Some people develop pain and redness at the injection site. [9] Use in pregnancy appears to be safe. [13] Severe allergic reactions occur in less than one in a million doses. [9] The first meningococcal vaccine became available in the 1970s. [15]
NmVac4-A/C/Y/W-135 is the commercial name for a polysaccharide vaccine that protects against meningococcal meningitis caused by Neisseria meningitidis, specifically the serotypes A, C, Y, and W-135. This vaccine is part of a broader group of meningococcal vaccines.
Penbraya is a pentavalent conjugate vaccine developed by Pfizer for the prevention of invasive meningococcal disease in people 10 through 25 years of age. [4] Invasive meningococcal disease, caused by the bacterium Neisseria meningitidis, can lead to serious conditions such as meningitis (inflammation of the brain and spinal cord lining) and sepsis. [5]
Non-infectious causes of meningitis include head injuries, adverse reactions to certain medications, cancer or autoimmune disorders like lupus or rheumatoid arthritis, says Dr. John Sellick, a ...
Pfizer’s new meningococcal vaccine, Penbraya, protects against five kinds of bacteria and could soon be an option that offers people broad protection from meningococcal disease with fewer shots.
“The vaccine helps prevent serious illnesses such as pneumonia, meningitis and bloodstream infections, which can be particularly dangerous for older adults and those with health issues,” Dr ...
A meningococcal polysaccharide vaccine (MPSV4) has been available since the 1970s and is the only meningococcal vaccine licensed for people older than 55. MPSV4 may be used in people 2–55 years old if the MCV4 vaccines are not available or contraindicated. Two meningococcal conjugate vaccines (MCV4) are licensed for use in the U.S. The first ...
The first vaccine to prevent meningococcal serogroup B (meningitis B) disease was approved by the European Commission on 22 January 2013. [12] Vaccines offer significant protection from three to five years (plain polysaccharide vaccine Menomune, Mencevax and NmVac-4) to more than eight years (conjugate vaccine Menactra). [13] [14]